CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Adding rusfertide to standard care can reduce the need for phlebotomy and improve symptoms in patients with polycythemia vera who require frequent phlebotomies, data suggest.

Phlebotomy on Wheels, a prominent mobile lab service provider, proudly announces its new staffing solutions aimed at empowering healthcare providers, including hospitals, doctors' offices, and nursing ...

Expelled, homeless, and ready to quit – this first-generation college student's path to her social work degree at Ferris ...

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a ...

PAVE recently hosted a graduation ceremony for PAVE East Texas students who have received their GED diploma as well as ...

Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also ...

Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus ...

A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

Mid and South Essex NHS Foundation Trust has signed a 15-year contract with SYNLAB for the delivery of a ‘hub and spoke’ ...